Janus Henderson Group PLC Buys 86,834 Shares of Carlsmed, Inc. $CARL

Janus Henderson Group PLC increased its position in shares of Carlsmed, Inc. (NASDAQ:CARL) by 7.6% during the first quarter, Holdings Channel reports. The institutional investor owned 1,227,452 shares of the company’s stock after purchasing an additional 86,834 shares during the quarter. Janus Henderson Group PLC’s holdings in Carlsmed were worth $11,108,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets bought a new stake in shares of Carlsmed in the 3rd quarter worth approximately $33,000. JPMorgan Chase & Co. acquired a new stake in shares of Carlsmed during the 3rd quarter worth approximately $37,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Carlsmed during the third quarter valued at approximately $42,000. Rhumbline Advisers acquired a new position in shares of Carlsmed in the third quarter valued at $79,000. Finally, Wells Fargo & Company MN raised its stake in shares of Carlsmed by 61.7% in the fourth quarter. Wells Fargo & Company MN now owns 7,834 shares of the company’s stock valued at $97,000 after purchasing an additional 2,989 shares in the last quarter.

Carlsmed Price Performance

Carlsmed stock opened at $13.43 on Wednesday. The company has a debt-to-equity ratio of 0.17, a current ratio of 11.88 and a quick ratio of 11.67. The company has a market capitalization of $365.03 million and a PE ratio of -5.35. Carlsmed, Inc. has a one year low of $8.50 and a one year high of $17.19. The business has a 50 day simple moving average of $11.40 and a 200 day simple moving average of $11.31.

Carlsmed (NASDAQ:CARL) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.11. Carlsmed had a negative return on equity of 60.74% and a negative net margin of 57.76%.The firm had revenue of $16.12 million for the quarter. On average, sell-side analysts forecast that Carlsmed, Inc. will post -1.47 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Weiss Ratings downgraded shares of Carlsmed from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 24th. Truist Financial dropped their price objective on shares of Carlsmed from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, April 15th. The Goldman Sachs Group reduced their price objective on shares of Carlsmed from $19.00 to $17.00 and set a “buy” rating for the company in a report on Thursday, April 9th. Wall Street Zen lowered shares of Carlsmed from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Finally, Needham & Company LLC initiated coverage on shares of Carlsmed in a research note on Wednesday, July 1st. They issued a “buy” rating and a $17.00 target price on the stock. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $18.75.

About Carlsmed

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).